Will Opdivo bring new turning point in treating lung cancer?
Opdivo has attracted interests if it could bring a new paradigm in treating lung cancer through acquiring the first domestic approval as a non-small cell lung cancer immune antibody.
Ono Pharma(CEO Ito Kynihiko) and BMS Pharmaceutical Korea(CEO Hye-sun Park) held a press conference on the 15th a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
